Physician profile
Mary E Boudreau
NPI 1730523598
$8,527.52
in general payments reported to CMS, 2019-2025
43 companies · $3,257 in 2025
The $3,257 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $1,026 · 2023: $1,632 · 2024: $2,302 · 2025: $3,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,181 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,180.51 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,974.22 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $1,657.61 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Glaxosmithkline, LLC. | $574.11 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $561.94 | 2021-2025 | |
| Novo Nordisk INC | $469.45 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $465.59 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Lilly USA, LLC | $383.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $247.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $181.06 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Biotech, INC. | $169.07 | 2021-2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $168.27 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.06 | 2024-2025 | Jardiance |
| Amgen INC. | $153.09 | 2023-2025 | Repatha, Otezla, Repatha |
| Eisai INC. | $134.08 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $120.41 | 2023 | Spravato |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Boudreau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.